Filing Flows

Filing Flows › Companies › CytomX Therapeutics › Cash flow

CytomX Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$16.1M in Q3 2026 · −$51.0M over twelve months

Operating cash flow$16.6M
Capital spending−$589K
Free cash flow+$16.1M

Analysis

In Q3 2026, CytomX Therapeutics generated $16.6M of operating cash flow and spent $589K on capital projects, leaving free cash flow of $16.1M. That is $31.5M more than in Q3 2025 (−$15.4M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$50.2M; the largest uses were other investing ($200M), operating cash flow ($50.2M), capital spending ($790K); besides operations, cash came from shares issued ($246M), other financing ($5.9M); the cash balance rose by $277K.

Operating cash flow was $16.6M against net income of −$20.0M. The largest differences: receivables +$37.0M, stock-based pay +$2.8M, prepaid and other assets −$2.7M.

Free cash flow

CytomX Therapeutics: free cash flow by quarterCytomX Therapeutics: free cash flow by quarter−$20.0MQ4 2024−$21.2MQ1 2025−$15.8MQ2 2025−$15.4MQ3 2025−$23.4MQ4 2025−$25.5MQ1 2026−$18.1MQ2 2026$16.1MQ3 2026
Operating cash flow less capital spending.
CytomX Therapeutics: operating cash flow against capital spendingCytomX Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$19.9M$80KQ4 2024−$21.0M$119KQ1 2025−$15.8M$27KQ2 2025−$15.5M−$127KQ3 2025−$23.2M$201KQ4 2025−$25.5M$0Q1 2026−$18.1M$0Q2 2026$16.6M$589KQ3 2026
Latest (Q3 2026): Operating cash flow $16.6M, Capital spending $589K.

Capital allocation, year by year

CytomX Therapeutics: where the cash came from (up) and went (down), by fiscal yearCytomX Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$119MFY2021: Shares issued $110MFY2021: Capital spending −$1.6M$110MFY2021FY2022: Operating cash flow −$111MFY2022: Shares issued $648KFY2022: Capital spending −$1.7M$648KFY2022FY2023: Operating cash flow −$56.0MFY2023: Shares issued $561KFY2023: Capital spending −$840K$561KFY2023FY2024: Operating cash flow −$86.2MFY2024: Shares issued $7.5MFY2024: Capital spending −$310K$7.5MFY2024FY2025: Operating cash flow −$75.6MFY2025: Shares issued $110MFY2025: Capital spending −$220K$110MFY2025
Over these 5 years operating cash flow totalled −$448M; the largest uses were operating cash flow ($448M) and capital spending ($4.7M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$348M
Debtnone
Net cash$348M
Cash runway6.8 years

CytomX Therapeutics is burning cash: its operations consume cash, a free cash flow of −$51.0M a year at the current rate against $348M of cash and investments: a runway of about 6.8 years before any new financing.

Where the cash came from and went

CytomX Therapeutics: sources (+) and uses (−) of cash, Q3 2026CytomX Therapeutics: sources (+) and uses (−) of cash, Q3 2026Cash drawn (+) / kept (−)−$16.7MOperating cash flow$16.6MCapital spending−$589KOther investing$586KShares issued$94K
CytomX Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026CytomX Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Shares issued$246MOther investing−$200MOperating cash flow−$50.2MOther financing$5.9MCapital spending−$790KCash drawn (+) / kept (−)−$277K

From profit to cash

CytomX Therapeutics: net income to operating cash flow, Q3 2026CytomX Therapeutics: net income to operating cash flow, Q3 2026Net income−$20.0MStock-based pay$2.8MReceivables$37.0MPayables−$932KDeferred revenue−$1.4MPrepaid and other assets−$2.7MOperating cash flow$16.6M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$16.6M−$589K$94K−$16.7M$16.1M
Q2 2026−$18.1M—$511K$11.6M−$18.1M
Q1 2026−$25.5M—$229M−$16.2M−$25.5M
Q4 2025−$23.2M−$201K$16.6M$21.0M−$23.4M
Q3 2025−$15.5M$127K$253K$14.9M−$15.4M
Q2 2025−$15.8M−$27K$93.5M−$1.4M−$15.8M
Q1 2025−$21.0M−$119K—−$9.6M−$21.2M
Q4 2024−$19.9M−$80K$2.2M$2.5M−$20.0M

CytomX Therapeutics: income statement and cash flow

CytomX Therapeutics, Q3 2026: revenue $1.7M (-72% year over year). The chart follows the revenue to costs, profit and cash.

CytomX Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.